Singapore authorities now reviewing telemed providers’ ads for weight-loss drugs
Lawyers say such advertisements may contravene a ban on ads for prescription medications
Add BT as a preferred source
SINGAPORE’S authorities are reviewing advertisements that telemedicine providers have put up for certain weight-loss drugs, while lawyers say that the providers could be in breach of a ban on advertisements of prescription-only medicines.
The telemedicine providers have put out ads for glucagon-like peptide 1 agonists, or GLP-1s, a class of drugs that are used to treat Type 2 diabetes but have gained attention for their effectiveness in aiding weight loss.
In response to queries, the Ministry of Health and the Health Sciences Authority said that they are reviewing the ads flagged by The Business Times and will take “appropriate enforcement action if any contraventions are detected”.
TRENDING NOW
On the board but frozen out: The Taib family feud tearing Sarawak construction giant apart
Thai and Vietnamese farmers may stop planting rice because of the Iran war. Here’s why
MAS convenes bank CEOs over AI cyberthreats; boards told to own risks, not leave to IT teams
Is it time to scrap COE categories for cars?
